Quantcast

Latest Glatiramer acetate Stories

2014-06-26 12:29:42

LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Multiple Sclerosis -- KOL Insight and Consensus Outlook Moduleshttp://www.reportbuyer.com/pharma_healthcare/diseases/multiple_sclerosis_kol_insight_consensus_outlook_modules.html IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen's Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market...

2014-05-27 08:28:11

NESS ZIONA, Israel, May 27, 2014 /PRNewswire/ -- Mapi Pharma Ltd. ("Mapi" or the "Company"), a developer of high-barrier to entry and high value-added generic drugs, announced today that its US patent for the company's Glatiramer Acetate Depot has been extended until December 2030. The notice of allowance for US Patent Application No. 13/258,808 entitled Depot Systems Comprising Glatiramer or Pharmacologically Acceptable Salt Thereof, also awarded additional claims to...

2014-05-15 08:31:31

PITTSBURGH, May 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today commented on the ruling by the U.S. District Court for the District of Columbia against Teva in their suit against the U.S. Food and Drug Administration (FDA), which denied Teva's motion to block FDA from approving generic versions of Copaxone® and dismissed the case for lack of jurisdiction. Mylan had intervened in this suit in support of FDA. http://photos.prnewswire.com/prnvar/20140423/77793 Mylan CEO...

2014-04-30 08:31:49

-- Conference Call Scheduled for Today, April 30, 2014 at 9 AM ET-- ROCKVILLE, Md., April 30, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, will host a conference call today to discuss in further detail the topline Phase II study results of Trimesta(TM) (oral estriol), which the Company is developing as a once-daily adjunctive...

2014-04-29 16:31:14

-- UCLA Researcher Reports Adjunctive Trimesta was Associated with Reduced Relapse Rate of 47 Percent -- ROCKVILLE, Md., April 29, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, reported today that the University of California, Los Angeles (UCLA) School of Medicine announced preliminary, positive topline data from the Phase II...

2014-04-25 08:28:05

ROCKLAND, Mass., April 25, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology's 66(th )Annual Meeting, taking place from April 26 - May 3, in Philadelphia, PA. http://photos.prnewswire.com/prnvar/20121220/SF32295LOGO-b Data from 14 study assessments presented by EMD Serono or its affiliate, Merck Serono, the...

2014-04-24 08:34:30

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 24, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Bristol-Myers Squibb Company (NYSE: BMY) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited...

2014-04-18 20:21:09

PITTSBURGH, April 18, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Supreme Court Chief Justice Roberts has denied Teva's application for an injunction seeking to prevent Mylan's launch of a generic version of Copaxone(®) pending the Supreme Court's decision on Teva's appeal. This is the second time that the Chief Justice has denied Teva's request for such an injunction. In March, the Supreme Court granted Teva's petition for certiorari seeking clarification of...

2014-04-15 12:30:41

Market Access Challenges for Sanofi/Genzyme's Aubagio Highlight the Hurdles New Multiple Sclerosis Agents Face in Europe, According to Findings from Decision Resources Group BURLINGTON, Mass., April 15, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed neurologists in France, Germany, Italy, Spain, and the United Kingdom (EU5) project that 16 percent of their diagnosed relapsing-remitting multiple sclerosis (MS) patients on average will receive Biogen Idec's Tecfidera within...

2014-04-08 12:25:22

U.S. Payers Are Sensitive to the Risk Profile of Novel Therapies When Making Formulary Decisions, According to Findings from Decision Resources Group BURLINGTON, Mass., April 8, 2014 /PRNewswire/ -- Decision Resources Group (DRG) finds that, for the treatment of primary-progressive multiple sclerosis (PP-MS), surveyed U.S. neurologists would be willing to accept a certain level of risk for a therapy with proven efficacy on disability progression, likely owing to the absence of approved...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related